


Steps for patient access to edaravone

1 You and your patient complete, sign, and submit a [Benefit Investigation and Enrollment Form](#) to the **JourneyMate Support Program™**.

- The **JourneyMate Support Program™** Insurance & Access Specialist conducts a benefit investigation of your patient's health insurance Pharmacy and Medical benefit coverage for RADICAVA ORS® (edaravone) and RADICAVA® (edaravone) IV, as appropriate
 - Help avoid unnecessary delays in patient access to therapy by providing documentation typically required, in order to assist your office with the Prior Authorization process*

Note: You may indicate a preferred formulation in Section 3.

Please check both boxes if you do not have a preference.



The form is titled "Radicava ORS (edaravone) Benefit Investigation and Enrollment Form Radicava (edaravone) IV". It contains three main sections: 1. PRESCRIBER OFFICE INFORMATION, 2. PATIENT INSURANCE INFORMATION, and 3. PRESCRIPTION INFORMATION. Section 3 includes two checkboxes: (Oral) RADICAVA ORS® and (IV) RADICAVA®. A red box highlights this section, and a red arrow points from the note to it.

- 2 The **Insurance & Access Specialist** provides your office and patient with a benefit summary and will:
- Indicate the formulation(s) covered by your patient's health plan
 - Send the prescription for RADICAVA ORS® to an in-network specialty pharmacy, which may assist your office in obtaining a final coverage determination
 - Help patients understand how to access RADICAVA® IV from an infusion therapy provider
- 3 If your patient's preferred formulation is denied by their health plan, you and your patient may consider:
- Starting treatment with the formulation approved by their health plan
 - Requesting an exception from the health plan for denial of coverage

Requesting an exception from the patient's health plan

If you have been notified that coverage of RADICAVA ORS® or RADICAVA® IV has been denied by the patient's health plan, a helpful guide called **Considerations for Understanding Coverage Determination** is available through your Mitsubishi Tanabe Pharma America Manager of Patient Access.

*May include, but are not limited to Letter of Medical Necessity, date of diagnosis, functional rating score information, and percent forced vital capacity (%FVC). Request a copy of **Coverage Determination Considerations for RADICAVA ORS®** from your Manager of Patient Access for more information.

See next steps based on formulation



Please see full [Prescribing Information](#).

Radicava ORS®
(edaravone) Oral Suspension
105mg/5mL

Radicava®
(edaravone) IV infusion
30mg/100mL

Next steps are based on formulation



Prescriber submits any additional required information to the specialty pharmacy, including Prior Authorization requirements.



Prescriber and patient decide on where to receive infusions.



Specialty pharmacy may help your office obtain a final coverage determination from the patient's health plan.



Infusion provider submits any additional required information to the patient's health plan.



Insurance & Access Specialist contacts the patient to discuss financial support options that may be available, **if eligible**.



Insurance & Access Specialist contacts the patient to discuss financial support options that may be available, **if eligible**.



When approval of coverage and payment are confirmed, specialty pharmacy applies available financial support, if eligible, and schedules delivery to the patient.



When approval of coverage is confirmed, the infusion provider schedules the patient's treatment with RADICAVA® IV.



Patient takes RADICAVA ORS® at home.



Patient receives RADICAVA® IV at the site of care, and the infusion provider applies available financial support, if eligible.

The dedicated Insurance & Access Specialist is ready to help you and your patient switch to the preferred formulation when coverage has been determined.

Provide patients with the [Steps on Your Way to Treatment](#) brochure, available at radicava.com.



Dedicated Team. Patient-Focused Approach.

Insurance & Access Specialist
1-844-772-4548
Monday-Friday, 8:00 AM-8:00 PM ET
radicavahcp.com

Please see full [Prescribing Information](#).

RADICAVA, RADICAVA ORS, the RADICAVA logo, and the corporate symbol of Mitsubishi Tanabe Pharma America are registered trademarks, and the RADICAVA ORS logo is a trademark, of Mitsubishi Tanabe Pharma Corporation. JourneyMate Support Program is a trademark of Mitsubishi Tanabe Pharma America, Inc.

For US healthcare professionals only.
Mitsubishi Tanabe Pharma America, Inc.
525 Washington Boulevard, Suite 400
Jersey City, NJ 07310

© 2022 Mitsubishi Tanabe Pharma America, Inc. All rights reserved. CP-RC-US-1392 11/22



Mitsubishi Tanabe Pharma America